Universal human papillomavirus vaccination of Australian boys — neither cost-effective nor equitable

Massey, Peter D; Durrheim, David N

doi:10.5694/mja12.10025

Topics

To the Editor: The possible extension of the Australian preadolescent female vaccination program against human papillomavirus (HPV) to preadolescent males is not a sensible use of public health resources.

1 School of Health, University of New England, Armidale, NSW.
2 School of Medicine and Public Health, University of Newcastle, Newcastle, NSW.

Correspondence: peter.massey@my.jcu.edu.au

Competing interests:

No relevant disclosures.

1. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29: 8443-8450.
2. Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sexual Health 2007; 4: 165-175.
3. Brisson M, Van de Velde N, Franco EL, et al. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011; 204: 372-376.
4. Palefsky J. Can HPV vaccination help to prevent anal cancer? Lancet Infect Dis 2010; 10: 815-816.
5. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378: 1461-1484.

Online responses are no longer available. Please refer to our instructions for authors page for more information.